Exagen (XGN) EBITDA (2018 - 2026)

Exagen has reported EBITDA for 9 years, with the latest figure at -$3.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 1.46% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$14.1 million (down 0.86% YoY), and the FY2025 full-year result was -$14.1 million, down 3.18% from the prior year.
• EBITDA for Q1 2026 stood at -$3.4 million, up from -$5.0 million in the prior quarter.
• The five-year high for EBITDA was -$2.6 million in Q2 2024, with the low at -$14.5 million in Q4 2022.
• Historically, EBITDA has averaged -$5.9 million across 5 years, with a median of -$4.9 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA sank 144.93% — and 2023, when it soared 65.05%.
• Exagen's EBITDA stood at -$14.5 million in 2022, then soared by 64.48% to -$5.1 million in 2023, then jumped by 34.27% to -$3.4 million in 2024, then tumbled by 47.06% to -$5.0 million in 2025, then jumped by 31.38% to -$3.4 million in 2026.
• The last three EBITDA figures came in at -$3.4 million (Q1 2026), -$5.0 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.